miRagen Moves to Next Level with $20M Series B
By Catherine Shaffer
Wednesday, April 25, 2012
miRagen Therapeutics Inc., of Boulder, Colo., completed a $20 million Series B financing that will help advance its unpartnered compounds toward clinical development.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.